Does Rallies show Form 4 insider transactions for EQ?

Yes. Rallies tracks EQ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EQ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EQ. It does not provide personalized investment advice.

EQ (Equillium, Inc. Common Stock) Stock Analysis - Insider Trades

Equillium, Inc. Common Stock (EQ) is a publicly traded Healthcare sector company. As of May 21, 2026, EQ trades at $2.13 with a market cap of $116.34M and a P/E ratio of -5.01. EQ moved +16.71% today. Year to date, EQ is +31.21%; over the trailing twelve months it is +434.65%. Its 52-week range spans $0.27 to $2.70. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces EQ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EQ stock inside the company?

Recent EQ insider activity includes Zedelmayer Christine sold 120.31K, Zedelmayer Christine sold 181.22K, Zedelmayer Christine sold 109.38K, Zedelmayer Christine sold 76.56K, and Zedelmayer Christine sold 109.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EQ Key Metrics

Key financial metrics for EQ
Metric	Value
Price	$2.13
Market Cap	$116.34M
P/E Ratio	-5.01
EPS	$-0.39
Dividend Yield	0.69%
52-Week High	$2.70
52-Week Low	$0.27
Volume	295.94K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-22.40M
Gross Margin	0.00%

Recent EQ Insider Trades

Zedelmayer Christine sold 120.31K (~$300.82K) on Mar 13, 2026.
Zedelmayer Christine sold 181.22K (~$362.44K) on Mar 9, 2026.
Zedelmayer Christine sold 109.38K (~$194.84K) on Feb 19, 2026.
Zedelmayer Christine sold 76.56K (~$133.26K) on Feb 19, 2026.
Zedelmayer Christine sold 109.38K (~$194.84K) on Feb 19, 2026.

Latest EQ News

Equillium to Host May 27 Webinar Revealing AhR Modulator and miR-124 Findings — May 20, 2026
Equillium Raises $35M, Names New CDO, EQ504 Phase 1 Trial Starts Mid-2026 — May 13, 2026
Equillium to Present EQ504 IL-10/IL-22 and Barrier Restoration Data at IMMUNOLOGY2026 — Apr 8, 2026
Equillium posts $22.4M 2025 net loss, secures $35M financing for EQ504 trial — Mar 25, 2026
Equillium Raises $35 Million via 18.9 Million Shares at $1.854 in PIPE Deal — Mar 13, 2026

EQ Analyst Consensus

6 analysts cover EQ: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.67.

Common questions about EQ

Who is trading EQ stock inside the company?: Recent EQ insider activity includes Zedelmayer Christine sold 120.31K, Zedelmayer Christine sold 181.22K, Zedelmayer Christine sold 109.38K, Zedelmayer Christine sold 76.56K, and Zedelmayer Christine sold 109.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EQ?: Yes. Rallies tracks EQ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EQ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EQ. It does not provide personalized investment advice.